$3.20
arrow_drop_down0.31%Performance History
| Key Stats | |
|---|---|
| Open | $3.21 |
| Prev. Close | $3.21 |
| EPS | -1.23 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $117.82M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 3.12 | 3.22 |
| 52 Week Range | 2.53 | 6.85 |
| Ratios | |
|---|---|
| Revenue | - |
| EBITDA Margin % | - |
| EPS | -1.23 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
About PDS Biotechnology (PDSB)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Frank K. Bedu-Addo Ph.D.
- Headquarters
- Florham Park
- Employees
- 26
- Exchange
- NASDAQ
Keep an eye on PDS Biotechnology
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
What is PDS Biotechnology's (PDSB) price per share?
What is the 52-week high and low for PDS Biotechnology (PDSB)?
Is PDS Biotechnology (PDSB) a growth stock?
What is PDS Biotechnology (PDSB) stock price performance year to date (YTD)?
Is PDS Biotechnology (PDSB) a profitable company?
What is the market capitalization of PDS Biotechnology (PDSB)?
News
PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
PDS Biotechnology Announces Details of Virtual KOL Event
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results